BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015;42:1051-1063. [PMID: 26304302 DOI: 10.1111/apt.13376] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
2 Goto M, Azuma K, Arima H, Kaneko S, Higashi T, Motoyama K, Michihara A, Shimizu T, Kadowaki D, Maruyama T, Otagiri M, Iohara D, Hirayama F, Anraku M. Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats. Life Sci 2021;268:118991. [PMID: 33417955 DOI: 10.1016/j.lfs.2020.118991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bhat M, Arendt BM, Bhat V, Renner EL, Humar A, Allard JP. Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol 2016; 8(27): 1128-1136 [PMID: 27721918 DOI: 10.4254/wjh.v8.i27.1128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
4 Wang X, Liu D, Wang Z, Cai C, Jiang H, Yu G. Porphyran-derived oligosaccharides alleviate NAFLD and related cecal microbiota dysbiosis in mice. FASEB J 2021;35:e21458. [PMID: 33948987 DOI: 10.1096/fj.202000763RRR] [Reference Citation Analysis]
5 Bajaj JS, Sterling RK, Betrapally NS, Nixon DE, Fuchs M, Daita K, Heuman DM, Sikaroodi M, Hylemon PB, White MB. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol Ther. 2016;44:638-643. [PMID: 27417456 DOI: 10.1111/apt.13732] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
6 Wellhöner F, Döscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M, Wedemeyer H, Heidrich B. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology 2021;74:72-82. [PMID: 33411981 DOI: 10.1002/hep.31700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 35.5] [Reference Citation Analysis]
8 Behrouz V, Aryaeian N, Zahedi MJ, Jazayeri S. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial.J Food Sci. 2020;85:3611-3617. [PMID: 32885440 DOI: 10.1111/1750-3841.15367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Anzola A, González R, Gámez-Belmonte R, Ocón B, Aranda CJ, Martínez-Moya P, López-Posadas R, Hernández-Chirlaque C, Sánchez de Medina F, Martínez-Augustin O. miR-146a regulates the crosstalk between intestinal epithelial cells, microbial components and inflammatory stimuli. Sci Rep 2018;8:17350. [PMID: 30478292 DOI: 10.1038/s41598-018-35338-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466. [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 34.0] [Reference Citation Analysis]
11 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
12 Chu X, Jin Q, Chen H, Wood GC, Petrick A, Strodel W, Gabrielsen J, Benotti P, Mirshahi T, Carey DJ, Still CD, DiStefano JK, Gerhard GS. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading. J Transl Med 2018;16:108. [PMID: 29690903 DOI: 10.1186/s12967-018-1490-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
13 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 21.3] [Reference Citation Analysis]
14 Derovs A, Laivacuma S, Krumina A. Targeting Microbiota: What Do We Know about It at Present? Medicina (Kaunas) 2019;55:E459. [PMID: 31405111 DOI: 10.3390/medicina55080459] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
15 Dai X, Guo Z, Chen D, Li L, Song X, Liu T, Jin G, Li Y, Liu Y, Ajiguli A, Yang C, Wang B, Cao H. Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood. Gut Microbes 2020;11:1043-63. [PMID: 32228300 DOI: 10.1080/19490976.2020.1738187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Pinto C, Ninfole E, Gaggiano L, Benedetti A, Marzioni M, Maroni L. Aging and the Biological Response to Liver Injury. Semin Liver Dis 2020;40:225-32. [PMID: 31887774 DOI: 10.1055/s-0039-3402033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Maiwall R, Gupta M. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. Transl Gastroenterol Hepatol 2020;5:18. [PMID: 32258522 DOI: 10.21037/tgh.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
19 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
20 DuPont HL, Jiang ZD, DuPont AW, Utay NS. Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation. Dig Dis Sci 2020;65:741-56. [PMID: 32008133 DOI: 10.1007/s10620-020-06102-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785-801. [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 56.0] [Reference Citation Analysis]
22 Fiorucci S, Biagioli M, Distrutti E. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res 2018;134:289-98. [PMID: 30021122 DOI: 10.1016/j.phrs.2018.07.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
23 Lee PC, Yang LY, Wang YW, Huang SF, Lee KC, Hsieh YC, Yang YY, Hsieh SL, Hou MC, Lin HC, Lee FY, Lee SD. Mechanisms of the prevention and inhibition of the progression and development of non-alcoholic steatohepatitis by genetic and pharmacological decoy receptor 3 supplementation. Hepatol Res 2017;47:1260-71. [PMID: 28066964 DOI: 10.1111/hepr.12863] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
24 Yin J, Lu J, Lei P, He M, Huang S, Lv J, Zhu Y, Liu Z, Jiang M. Danggui-Shaoyao-San Improves Gut Microbia Dysbiosis and Hepatic Lipid Homeostasis in Fructose-Fed Rats. Front Pharmacol 2021;12:671708. [PMID: 34326769 DOI: 10.3389/fphar.2021.671708] [Reference Citation Analysis]
25 Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health 2021;40:50-8. [PMID: 33520569 DOI: 10.12938/bmfh.2020-046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 刘旭东, 吕萍, 赵壮志, 徐新杰. 非酒精性脂肪性肝病对全身多系统的影响. 世界华人消化杂志 2017; 25(11): 951-957 [DOI: 10.11569/wcjd.v25.i11.951] [Reference Citation Analysis]
27 Porras D, Nistal E, Martínez-Flórez S, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S. Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Front Physiol 2018;9:1813. [PMID: 30618824 DOI: 10.3389/fphys.2018.01813] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
28 Wilechansky RM, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver Int 2019;39:1535-44. [PMID: 31033142 DOI: 10.1111/liv.14125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
29 Eom T, Ko G, Kim KC, Kim JS, Unno T. Dendropanax morbifera Leaf Extracts Improved Alcohol Liver Injury in Association with Changes in the Gut Microbiota of Rats. Antioxidants (Basel) 2020;9:E911. [PMID: 32987739 DOI: 10.3390/antiox9100911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Peng M, Tabashsum Z, Anderson M, Truong A, Houser AK, Padilla J, Akmel A, Bhatti J, Rahaman SO, Biswas D. Effectiveness of probiotics, prebiotics, and prebiotic-like components in common functional foods. Compr Rev Food Sci Food Saf 2020;19:1908-33. [PMID: 33337097 DOI: 10.1111/1541-4337.12565] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
31 Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192-202. [PMID: 29083037 DOI: 10.1111/apt.14397] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 19.5] [Reference Citation Analysis]
32 Dong Y, Lu J, Wang T, Huang Z, Chen X, Ren Z, Hong L, Wang H, Yang D, Xie H, Zhang W. Multi-Omics Analysis Reveals Disturbance of Nanosecond Pulsed Electric Field in the Serum Metabolic Spectrum and Gut Microbiota. Front Microbiol 2021;12:649091. [PMID: 34276585 DOI: 10.3389/fmicb.2021.649091] [Reference Citation Analysis]
33 Bibbò S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators Inflamm 2018;2018:9321643. [PMID: 29563854 DOI: 10.1155/2018/9321643] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]
34 Zhang Z, Zhou H, Guan M, Zhou X, Liang X, Lv Y, Bai L, Zhang J, Gong P, Liu T, Yi H, Wang J, Zhang L. Lactobacillus casei YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice. Br J Nutr 2021;125:1081-91. [PMID: 32718364 DOI: 10.1017/S0007114520003013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF, Chen MX, Chen ZH, Ji GY, Zheng ZD, Mujagond P, Chen XJ, Rong ZH, Chen P, Lyu LY, Wang X, Wu CB, Yu N, Xu YJ, Yin J, Raes J, Knight R, Ma WJ, Zhou HW. Regional variation limits applications of healthy gut microbiome reference ranges and disease models.Nat Med. 2018;24:1532-1535. [PMID: 30150716 DOI: 10.1038/s41591-018-0164-x] [Cited by in Crossref: 279] [Cited by in F6Publishing: 258] [Article Influence: 93.0] [Reference Citation Analysis]
36 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Fiorucci S, Biagioli M, Zampella A, Distrutti E. Bile Acids Activated Receptors Regulate Innate Immunity. Front Immunol 2018;9:1853. [PMID: 30150987 DOI: 10.3389/fimmu.2018.01853] [Cited by in Crossref: 123] [Cited by in F6Publishing: 118] [Article Influence: 41.0] [Reference Citation Analysis]
38 Takahashi S, Luo Y, Ranjit S, Xie C, Libby AE, Orlicky DJ, Dvornikov A, Wang XX, Myakala K, Jones BA, Bhasin K, Wang D, McManaman JL, Krausz KW, Gratton E, Ir D, Robertson CE, Frank DN, Gonzalez FJ, Levi M. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice. J Biol Chem 2020;295:4733-47. [PMID: 32075905 DOI: 10.1074/jbc.RA119.011913] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
39 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 103.0] [Reference Citation Analysis]
40 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
41 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
42 Friedman JE, Dobrinskikh E, Alfonso-Garcia A, Fast A, Janssen RC, Soderborg TK, Anderson AL, Reisz JA, D'Alessandro A, Frank DN, Robertson CE, de la Houssaye BA, Johnson LK, Orlicky DJ, Wang XX, Levi M, Potma EO, El Kasmi KC, Jonscher KR. Pyrroloquinoline quinone prevents developmental programming of microbial dysbiosis and macrophage polarization to attenuate liver fibrosis in offspring of obese mice. Hepatol Commun 2018;2:313-28. [PMID: 29507905 DOI: 10.1002/hep4.1139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
43 Jobira B, Frank DN, Silveira LJ, Pyle L, Kelsey MM, Garcia-Reyes Y, Robertson CE, Ir D, Nadeau KJ, Cree-Green M. Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome. PLoS One 2021;16:e0245219. [PMID: 33465100 DOI: 10.1371/journal.pone.0245219] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Loman BR, Hernández-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev 2018;76:822-39. [PMID: 30113661 DOI: 10.1093/nutrit/nuy031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 19.0] [Reference Citation Analysis]
45 Pyo JH, Kim TJ, Lee H, Choi SC, Cho SJ, Choi YH, Min YW, Min BH, Lee JH, Kang M, Lee YC, Kim JJ. Proton pump inhibitors use and the risk of fatty liver disease: A nationwide cohort study. J Gastroenterol Hepatol 2021;36:1235-43. [PMID: 32886822 DOI: 10.1111/jgh.15236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 28.8] [Reference Citation Analysis]
47 Fang J, Sun X, Xue B, Fang N, Zhou M. Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier. Evid Based Complement Alternat Med 2017;2017:2945803. [PMID: 29259643 DOI: 10.1155/2017/2945803] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
48 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
49 Zhang Y, Li JX, Zhang Y, Wang YL. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis . World J Clin Cases 2021; 9(23): 6654-6662 [PMID: 34447812 DOI: 10.12998/wjcc.v9.i23.6654] [Reference Citation Analysis]
50 Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
51 He X, Ji G, Jia W, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci. 2016;17:300. [PMID: 26999104 DOI: 10.3390/ijms17030300] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
52 Gómez-Zorita S, Aguirre L, Milton-Laskibar I, Fernández-Quintela A, Trepiana J, Kajarabille N, Mosqueda-Solís A, González M, Portillo MP. Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models. Nutrients 2019;11:E2156. [PMID: 31505802 DOI: 10.3390/nu11092156] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
53 Wesolowski SR, Kasmi KC, Jonscher KR, Friedman JE. Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol 2017;14:81-96. [PMID: 27780972 DOI: 10.1038/nrgastro.2016.160] [Cited by in Crossref: 72] [Cited by in F6Publishing: 80] [Article Influence: 14.4] [Reference Citation Analysis]
54 Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:319-31. [DOI: 10.1111/apt.13858] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 14.6] [Reference Citation Analysis]
55 Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017;2:211-23. [PMID: 28404136 DOI: 10.1016/S2468-1253(16)30120-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
56 Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2018;47:16-25. [DOI: 10.1111/apt.14401] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
57 Kuraji R, Sekino S, Kapila Y, Numabe Y. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. Periodontol 2000 2021;87:204-40. [PMID: 34463983 DOI: 10.1111/prd.12387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Jian C, Luukkonen P, Sädevirta S, Yki-Järvinen H, Salonen A. Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clin Nutr 2021;40:207-16. [PMID: 32536582 DOI: 10.1016/j.clnu.2020.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
59 Bluemel S, Wang Y, Lee S, Schnabl B. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World J Gastroenterol 2020; 26(33): 4933-4944 [PMID: 32952340 DOI: 10.3748/wjg.v26.i33.4933] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Xue L, He J, Gao N, Lu X, Li M, Wu X, Liu Z, Jin Y, Liu J, Xu J, Geng Y. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017;7:45176. [PMID: 28349964 DOI: 10.1038/srep45176] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 24.0] [Reference Citation Analysis]
61 Thongprayoon C, Kaewput W, Hatch ST, Bathini T, Sharma K, Wijarnpreecha K, Ungprasert P, D'Costa M, Mao MA, Cheungpasitporn W. Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysis. Dig Dis Sci 2019;64:469-79. [PMID: 30099652 DOI: 10.1007/s10620-018-5243-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
62 Li Y, Liu T, Yan C, Xie R, Guo Z, Wang S, Zhang Y, Li Z, Wang B, Cao H. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier. Mol Pharm 2018;15:3860-70. [PMID: 30036479 DOI: 10.1021/acs.molpharmaceut.8b00347] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
63 Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1246-1267. [PMID: 26809873 DOI: 10.1007/s10620-016-4040-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 12.6] [Reference Citation Analysis]
64 Pérez-Matute P, Oteo JA. Is it enough to eliminate hepatitis C virus to reverse the damage caused by the infection? World J Clin Infect Dis 2017; 7(1): 1-5 [DOI: 10.5495/wjcid.v7.i1.1] [Reference Citation Analysis]
65 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(31): 7006-7016 [PMID: 27610012 DOI: 10.3748/wjg.v22.i31.7006] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 94] [Article Influence: 19.6] [Reference Citation Analysis]
67 Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020;14:127-35. [PMID: 31928239 DOI: 10.1080/17474124.2020.1715210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
69 Ahmad S, Bromberg JS. Current status of the microbiome in renal transplantation. Curr Opin Nephrol Hypertens. 2016;25:570-576. [PMID: 27517135 DOI: 10.1097/mnh.0000000000000262] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
70 Furuta K, Guo Q, Hirsova P, Ibrahim SH. Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis. Biology (Basel) 2020;9:E395. [PMID: 33198153 DOI: 10.3390/biology9110395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
71 Soderborg TK, Clark SE, Mulligan CE, Janssen RC, Babcock L, Ir D, Young B, Krebs N, Lemas DJ, Johnson LK, Weir T, Lenz LL, Frank DN, Hernandez TL, Kuhn KA, D'Alessandro A, Barbour LA, El Kasmi KC, Friedman JE. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun. 2018;9:4462. [PMID: 30367045 DOI: 10.1038/s41467-018-06929-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 28.7] [Reference Citation Analysis]
72 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 20.0] [Reference Citation Analysis]
73 Hanson A, Piras IS, Wilhelmsen D, Still CD, Chu X, Petrick A, Gerhard GS, DiStefano JK. Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p. Cytokine 2019;123:154789. [PMID: 31352173 DOI: 10.1016/j.cyto.2019.154789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
74 Li F, Hao X, Chen Y, Bai L, Gao X, Lian Z, Wei H, Sun R, Tian Z. The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner. Nat Commun 2017;7:13839. [PMID: 28067223 DOI: 10.1038/ncomms13839] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 15.8] [Reference Citation Analysis]
75 Jung Y, Kim I, Mannaa M, Kim J, Wang S, Park I, Kim J, Seo YS. Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease. Food Sci Biotechnol 2019;28:261-7. [PMID: 30815318 DOI: 10.1007/s10068-018-0433-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
76 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. Hepatol Res 2020;50:407-18. [PMID: 31840358 DOI: 10.1111/hepr.13473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
78 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
79 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
80 Nash MJ, Frank DN, Friedman JE. Early Microbes Modify Immune System Development and Metabolic Homeostasis-The "Restaurant" Hypothesis Revisited. Front Endocrinol (Lausanne). 2017;8:349. [PMID: 29326657 DOI: 10.3389/fendo.2017.00349] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
81 Villard A, Boursier J, Andriantsitohaina R. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis? Am J Physiol Gastrointest Liver Physiol 2021;320:G485-95. [PMID: 33471632 DOI: 10.1152/ajpgi.00362.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Li J, Sasaki GY, Dey P, Chitchumroonchokchai C, Labyk AN, McDonald JD, Kim JB, Bruno RS. Green tea extract protects against hepatic NFκB activation along the gut-liver axis in diet-induced obese mice with nonalcoholic steatohepatitis by reducing endotoxin and TLR4/MyD88 signaling. J Nutr Biochem 2018;53:58-65. [PMID: 29190550 DOI: 10.1016/j.jnutbio.2017.10.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
83 Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021;9:51-9. [PMID: 33604255 DOI: 10.14218/JCTH.2020.00057] [Reference Citation Analysis]
84 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
85 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 300] [Article Influence: 150.5] [Reference Citation Analysis]
86 Lucchetti M, Kaminska M, Oluwasegun AK, Mosig AS, Wilmes P. Emulating the gut-liver axis: Dissecting the microbiome's effect on drug metabolism using multiorgan-on-chip models. Curr Opin Endocr Metab Res 2021;18:94-101. [PMID: 34239997 DOI: 10.1016/j.coemr.2021.03.003] [Reference Citation Analysis]
87 Choudhary AK, Lee Y. Dysregulated microbiota-gut-brain axis: Does it explain aspartame metabolic and other side-effects? NFS 2017;47:648-58. [DOI: 10.1108/nfs-03-2017-0034] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
88 Schröder T, Kucharczyk D, Bär F, Pagel R, Derer S, Jendrek ST, Sünderhauf A, Brethack AK, Hirose M, Möller S, Künstner A, Bischof J, Weyers I, Heeren J, Koczan D, Schmid SM, Divanovic S, Giles DA, Adamski J, Fellermann K, Lehnert H, Köhl J, Ibrahim S, Sina C. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Mol Metab 2016;5:283-95. [PMID: 27069868 DOI: 10.1016/j.molmet.2016.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
89 Chen J, Liu J, Yan C, Zhang C, Pan W, Zhang W, Lu Y, Chen L, Chen Y. Sarcodon aspratus polysaccharides ameliorated obesity-induced metabolic disorders and modulated gut microbiota dysbiosis in mice fed a high-fat diet. Food Funct 2020;11:2588-602. [DOI: 10.1039/c9fo00963a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
90 Zeng W, Shan W, Gao L, Gao D, Hu Y, Wang G, Zhang N, Li Z, Tian X, Xu W. Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. Sci Rep. 2015;5:16013. [PMID: 26525891 DOI: 10.1038/srep16013] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
91 Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol 2019;12:1756284819858470. [PMID: 31258623 DOI: 10.1177/1756284819858470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
92 Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Front Med. 2018;12:645-657. [PMID: 30178233 DOI: 10.1007/s11684-018-0645-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
93 Cheng D, Song J, Xie M, Song D. The bidirectional relationship between host physiology and microbiota and health benefits of probiotics: A review. Trends in Food Science & Technology 2019;91:426-35. [DOI: 10.1016/j.tifs.2019.07.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
94 Cogger VC, Mohamad M, Solon-Biet SM, Senior AM, Warren A, O'Reilly JN, Tung BT, Svistounov D, McMahon AC, Fraser R, Raubenheimer D, Holmes AJ, Simpson SJ, Le Couteur DG. Dietary macronutrients and the aging liver sinusoidal endothelial cell. Am J Physiol Heart Circ Physiol. 2016;310:H1064-H1070. [PMID: 26921440 DOI: 10.1152/ajpheart.00949.2015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
95 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Reference Citation Analysis]
96 Rivero-Gutiérrez B, Gámez-Belmonte R, Suárez MD, Lavín JL, Aransay AM, Olivares M, Martínez-Augustin O, Sánchez de Medina F, Zarzuelo A. A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota. Mol Nutr Food Res 2017;61. [PMID: 28463404 DOI: 10.1002/mnfr.201600622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
97 Moura FA, de Andrade KQ, de Araújo OR, Nunes-Souza V, Santos JC, Rabelo LA, Goulart MO. Colonic and Hepatic Modulation by Lipoic Acid and/or N-Acetylcysteine Supplementation in Mild Ulcerative Colitis Induced by Dextran Sodium Sulfate in Rats. Oxid Med Cell Longev 2016;2016:4047362. [PMID: 27957238 DOI: 10.1155/2016/4047362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]